CLINICAL COMPARISON OF ORAL NIFEDIPINE AND SUBCUTANEOUS TERBUTALINE FOR INITIAL TOCOLYSIS

被引：24

作者：

SMITH, CS

WOODLAND, MB

机构：

[1] Division of Maternal-Fetal Medicine, Department Obstetrics and Gynecology, Community Medical Center Hospital, Scranton

[2] and Department of Obstetrics and Gynecology, Robert Wood Johnson Medical School at Camden (UMDNJ), Cooper Hospital/University Medical Center, Academic Affiliation with Department of Maternal-Fetal Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania

来源：

AMERICAN JOURNAL OF PERINATOLOGY | 1993年 / 10卷 / 04期

关键词：

D O I：

10.1055/s-2007-994740

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

In search of further ''first line'' alternatives for reducing premature uterine irritability and contractions, oral nifedipine, a type II dihydropyridine calcium channel blocking agent, was selected for a prospective randomized comparison trial with an established subcutaneous terbutaline protocol. Patients without primary exclusion criteria for tocolysis, with gestational ages between 20 and 35 weeks, were eligible for the study. In this report, data from 52 patients have been collated and have undergone appropriate tests of significance (28 patients receiving nifedipine and 24 patients receiving terbutaline). Both agents were found to be highly effective for tocolysis, with a success rate of 68% for nifedipine and 71% for terbutaline. Although not statistically significant, a tendency toward a decrease in side effects was noted with nifedipine when compared with terbutaline. No deleterious maternal or fetal side effects were reported. Based on these data, nifedipine, given as a one time, 30 mg oral dose, proved to be as effective as the subcutaneous terbutaline injection protocol.

引用

页码：280 / 284

页数：5

共 26 条

[1]

Givens S.R., Update on tocolytic therapy in the managementof preterm labor, Perinat Neonatal Nurs, 2, pp. 21-32, (1988)

[2]

Marston S., Calcium ion-dependent regulation of uterinesmooth muscle filaments by caldesmon, Am J Obstet Gynecol, 160, pp. 252-257, (1989)

[3]

Ulmsten U., Andersson K.R., Wingerup L., Treatment of premature labor with calcium agonist nifedipine, Arch Gynecol, 2, 290, pp. 1-5, (1980)

[4]

Carsten M.K., Miller J.D., A new look at uterine muscle contraction, Am J äbstet Gynecol, 157, pp. 1303-1315, (1987)

[5]

Forman A., Gandrup P., Andersson K.E., Ulmsten U., Effectsof nifedipine on spontaneous and methylergometrine-induced activity postpartum, Am J Obstet Gynecol, 144, pp. 442-448, (1982)

[6]

Maigaar S., Forman A., Andersson K.F., Ulmsten U., Comparison of effects of nicardipine and nifedipine on isolated human myometrium, Gyneocl Obstet Invest, 16, pp. 354-366, (1983)

[7]

Hahn D.V., McGuire J.L., Vanderhoof M., Ericson E., Pasquale S.A., Evaluation of drugs for arrest of premature in a new animal model, Am J Obstet Gynecol, 148, pp. 775-778, (1984)

[8]

Forman A., Gandrup P., Andersson K.E., Ulmsten U., Effectsof nifedipine on oxytocin- and prostaglandin F2-induced activity in the postpartum uterus, Am J Obstet Gynecol, 144, pp. 655-670, (1982)

[9]

Ulmsten U., Treatment of normolensive and hypertensivepatients with preterm labor using oral nifedipine, a calcium agonist, Arch Gynecol, 236, pp. 69-72, (1984)

[10]

Bussey H.I., Talbel R.L., Promising uses of calcium channelblocking agents, Pharmacotherapy, 4, pp. 137-143, (1984)

← 1 2 3 →